These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8056857)

  • 1. Dyslipidemia: drugs, diet, and common sense.
    Kuritzky L
    Hosp Pract (Off Ed); 1994 Aug; 29(8):40-1, 44. PubMed ID: 8056857
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of baseline levels on response of high-density lipoprotein cholesterol to hypolipidemic treatment.
    Kolovou GD; Daskalova DC; Petropoulos II; Anagnostopoulou KK; Bilianou HI; Pilatis ND; Pavlidis AN; Cokkinos DV
    Am J Cardiol; 2003 Dec; 92(11):1339-42. PubMed ID: 14636917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary prevention of ischaemic heart disease with lipid-lowering drugs.
    Lancet; 1988 Feb; 1(8581):333-4. PubMed ID: 2893141
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of intensive diet and exercise intervention in patients taking cholesterol-lowering drugs.
    Barnard RJ; DiLauro SC; Inkeles SB
    Am J Cardiol; 1997 Apr; 79(8):1112-4. PubMed ID: 9114776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Currently available lipid-lowering agents.
    Levy RI
    Hosp Pract (Off Ed); 1988 Jun; 23 Suppl 1():14-21. PubMed ID: 3134381
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of hyperlipidemia. Diet and drugs.
    Steinberg D; Grundy SM
    Arch Surg; 1978 Jan; 113(1):55-60. PubMed ID: 619861
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapy and clinical trials.
    Cramb R
    Curr Opin Lipidol; 1998 Aug; 9(4):381-3. PubMed ID: 9739497
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical trial of gugulipid--a new hypolipidemic agent of plant origin in primary hyperlipidemia.
    Agarwal RC; Singh SP; Saran RK; Das SK; Sinha N; Asthana OP; Gupta PP; Nityanand S; Dhawan BN; Agarwal SS
    Indian J Med Res; 1986 Dec; 84():626-34. PubMed ID: 3552974
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of halofenate on serum lipids.
    Aronow WS; Harding PR; Khursheed M; Vangrow JS; Papageorge's NP; Mays J
    Clin Pharmacol Ther; 1973; 14(3):358-65. PubMed ID: 4572798
    [No Abstract]   [Full Text] [Related]  

  • 10. Dietary and pharmacologic therapy for the lipid risk factors.
    JAMA; 1983 Oct; 250(14):1873-9. PubMed ID: 6620484
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical evaluation of tibric acid (CP 18,524) a new hypolipidemic agent.
    Sirtori CR; Zoppi S; Quarisa B; Agradi E
    Pharmacol Res Commun; 1974 Oct; 6(5):445-56. PubMed ID: 4617230
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of CH 13.437 in different types of hyperlipidemia.
    Harvengt C
    Arch Int Pharmacodyn Ther; 1972 Apr; 196():Suppl 196:298+. PubMed ID: 4559547
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapy and clinical trials.
    Curr Opin Lipidol; 1997 Dec; 8(6):B77-85. PubMed ID: 9412779
    [No Abstract]   [Full Text] [Related]  

  • 14. Medical management of hyperlipidemia/dyslipidemia.
    Kreisberg RA; Oberman A
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2445-61. PubMed ID: 12788840
    [No Abstract]   [Full Text] [Related]  

  • 15. Response of high-density lipoproteins to hypolipidemic drugs according to their initial level.
    Kolovou GD; Fostinis YP; Bilianou HI; Cokkinos DV
    Am J Cardiol; 1995 Feb; 75(4):293-5. PubMed ID: 7832145
    [No Abstract]   [Full Text] [Related]  

  • 16. Inclusion of lipoprotein subfractions among efficacy parameters.
    Superko HR
    Am J Cardiol; 1998 Apr; 81(8A):52F-55F. PubMed ID: 9604909
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of primary hyperlipoproteinaemias with a tetralin derivative (Su-13'437).
    Fellin R; Fedele D; Bagnariol G; Pagnan A; Crepaldi G
    Atherosclerosis; 1973; 17(3):383-8. PubMed ID: 4577009
    [No Abstract]   [Full Text] [Related]  

  • 18. Updating a 12-year experience with arrest and reversal therapy for coronary heart disease (an overdue requiem for palliative cardiology).
    Esselstyn CB
    Am J Cardiol; 1999 Aug; 84(3):339-41, A8. PubMed ID: 10496449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of the uricosuric action of the hypolipidemic drug halofenate.
    Ravenscroft PJ; Sands JM; Emmerson BT
    Clin Pharmacol Ther; 1973; 14(4):547-51. PubMed ID: 4723262
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-benefit analysis of lipid lowering therapy.
    Davie AP; McMurray JJ
    Eur Heart J; 1996 Jul; 17(7):974-5. PubMed ID: 8809507
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.